ARWR SP does not fairly value this deal Arrowhead
Post# of 226
Posted On: 01/14/2013 7:42:10 PM
ARWR SP does not fairly value this deal
Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that it has signed a research collaboration and license agreement with Shire AG, to develop and commercialize targeted peptide-drug conjugates (PDCs) by utilizing Arrowhead’s human-derived Homing Peptide platform and Shire’s therapeutic payloads. Arrowhead will receive research funding and could be eligible for development, regulatory, and commercialization milestone payments of up to $32.8 million for each development candidate, plus additional milestone payments for a second indication, and royalties on worldwide sales. Additional financial terms of the agreement were not disclosed
(0)
(0)Scroll down for more posts ▼